Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPN-810 Neuroimaging Study for Impulsive Aggression in ADHD
NCT03638466Phase 2Terminated
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Start
- May 2019
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of molindone in intermittent explosive disorder (IED), sponsored by Supernus Pharmaceuticals, Inc.. Started May 2019; status: terminated.
02
Drugs
molindone
03
Conditions
intermittent explosive disorder (IED)
Beyond the preview
Go deeper on NCT03638466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03638466.